These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 18464770)

  • 1. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 2. From laboratory to medicine cabinet.
    Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 4. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 7. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 8. How pharmaceuticals are developed.
    Vander Elst E
    J Am Dent Assoc; 1994 Jan; 125 Suppl():40S-44S. PubMed ID: 8294674
    [No Abstract]   [Full Text] [Related]  

  • 9. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 10. Trading on traditional medicines.
    Basu P
    Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
    [No Abstract]   [Full Text] [Related]  

  • 11. A Food and Drug Administration primer.
    Simon LS
    Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
    [No Abstract]   [Full Text] [Related]  

  • 12. Translation of cancer immunotherapies.
    Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ
    Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901
    [No Abstract]   [Full Text] [Related]  

  • 13. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 14. Advancing Alzheimer's disease drug review as a national priority.
    Perry DP
    Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 16. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefit the patient, manage the risk: a system goal.
    Califf RM
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):269-76. PubMed ID: 15133777
    [No Abstract]   [Full Text] [Related]  

  • 18. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 20. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.